Deepak Fertilisers & Petrochemicals Corp Ltd: A Diversified Chemicals Powerhouse With Unique Market Positioning

Deep Dive Equity Research | NiftyBrief

Deepak Fertilisers and Petrochemicals Corporation Ltd (NSE: DEEPAKFERT, BSE: 500645) is one of India's most uniquely positioned chemical and fertilizer companies. Incorporated in 1979, the company has evolved from a single-product fertilizer manufacturer into a diversified conglomerate spanning industrial chemicals, crop nutrition, mining explosives, and real estate. As of June 1, 2026, the stock trades at ₹1,411 on the NSE, commanding a market capitalization of ₹17,807 crore.

This comprehensive research article examines Deepak Fertilisers' financial performance, business segments, peer positioning, balance sheet strength, and investment outlook using the latest available data.

Company Overview and Business Segments

Deepak Fertilisers operates across multiple verticals, giving it a rare diversification advantage in the Indian chemicals space. The company's businesses span:

• Industrial Chemicals: The company is India's only manufacturer of Prilled and Medical-grade Ammonium Nitrate, a critical input for mining, infrastructure, and defence applications.
• Fertilizers & Agri Services: Deepak is the only manufacturer of NP prill 24:24:0 fertilizer in India and a market leader in Bentonite Sulphur, specialty fertilizers, and water-soluble fertilizers.
• Mining Chemicals (TAN – Technical Ammonium Nitrate): A key supplier to India's mining and construction sectors with backward-integrated production.
• IPA (Isopropyl Alcohol): The company is a leading manufacturer and marketer of IPA in India, serving pharmaceutical, cosmetic, and industrial cleaning sectors.
• Real Estate: An emerging vertical that adds asset backing to the business.

This diversification insulates the company from cyclicality in any single segment. While fertilizer pricing is often influenced by government policy and subsidy regimes, the industrial chemicals and mining chemicals segments offer market-linked pricing and better margin visibility.

Stock Price and Valuation Snapshot

As of the close on June 1, 2026, here are the key valuation metrics:

The stock is currently trading 20.7% below its 52-week high of ₹1,779 and 63.1% above its 52-week low of ₹865, indicating a wide trading range over the past year. At a P/E of 24.2x, the stock is reasonably valued compared to high-growth chemical peers like SRF (P/E 42.0x) but commands a premium over value plays like G N FC (P/E 9.08x) and GHCL (P/E 8.95x).

The price-to-book ratio of 2.60x suggests the market is pricing in growth beyond the current asset base. With a book value of ₹542 per share, the stock trades at a meaningful premium, reflecting expectations of future earnings improvement.

Quarterly Financial Performance: A Detailed Look

Revenue Trajectory

The quarterly results reveal a company with improving revenue momentum. Let's examine the last 13 quarters from March 2023 to March 2026:

Revenue has shown a clear upward trend, with the most recent quarter (March 2026) delivering the highest quarterly sales of ₹3,011 crore in the dataset. This represents a 44.3% jump from the cyclical low of ₹2,086 crore in March 2024 and marks a solid recovery from the December 2023 trough of ₹1,853 crore. The trailing twelve months (TTM) revenue stands at approximately ₹11,506 crore, a company record.

Operating Profitability

Operating profit margins have been volatile but generally healthy:

The operating profit peaked at ₹513 crore in June 2025 with a 19% margin, but has since contracted to ₹354 crore in March 2026 with margins compressing to 12%. This margin compression is a key concern, likely driven by rising raw material costs, higher interest expenses, and competitive pricing pressures. The most recent two quarters (December 2025 and March 2026) showed OPM of just 12%, down from the 18-21% range seen in the first half of FY25.

Net Profit and EPS

Net profit has declined sharply in the second half of FY26. The March 2026 quarter reported a net profit of just ₹139 crore (EPS ₹11.04), a 50% drop from the March 2025 figure of ₹278 crore (EPS ₹21.96). The trailing EPS for FY26 stands at approximately ₹58.40, down from ₹73.95 in FY25 — a 21% decline year-on-year. This earnings contraction is the primary driver behind the stock's correction from its 52-week high.

The effective tax rate has been volatile, ranging from 13% to 46% across quarters, with the March 2026 quarter seeing a tax rate of just 13% — suggesting possible tax benefits or adjustments that partially cushioned the profit decline.

Annual Financial Performance: Long-Term Trends

Profit & Loss Summary (FY2015–FY2026)

The annual P&L tells a story of strong growth over the decade:

Key observations from the annual data:

• Revenue has grown at a 10-year CAGR of approximately 13%, rising from ₹3,808 crore in FY15 to ₹11,506 crore in FY26.
• Revenue grew 12% year-on-year from FY25 to FY26, reaching an all-time high of ₹11,506 crore.
• Operating profit margins expanded dramatically from 8% in FY15 to a peak of 19% in FY23 and FY25, but have corrected to 15% in FY26.
• Net profit grew from just ₹67 crore in FY15 to a peak of ₹1,221 crore in FY23, before moderating. The FY26 net profit of ₹739 crore is down 21.8% from FY25's ₹945 crore.
• EPS peaked at ₹95.86 in FY23 and currently stands at ₹58.40 in FY26.
• The dividend payout ratio has averaged around 18.1% over recent years, declining from the 52% payout in FY15 as the company retained more earnings for growth capex.

Sales Growth CAGR

The company's sales growth trajectory:

• 10-Year CAGR: 13%
• 5-Year CAGR: 15%
• 3-Year CAGR: 12%
• 1-Year Growth: 11%

This consistent double-digit growth underscores the company's ability to scale its diversified business model.

Balance Sheet Analysis: Growing Asset Base

Key Balance Sheet Metrics (FY2015–FY2026)

Balance Sheet Highlights:

• Total assets have expanded from ₹3,440 crore in FY15 to ₹16,488 crore in FY26, a nearly 5x increase over the decade.
• Equity capital has remained stable at ₹126 crore since FY23, with the face value of ₹10.
• Reserves have compounded from ₹1,384 crore to ₹6,718 crore, reflecting strong retained earnings growth.
• Borrowings have increased significantly to ₹5,670 crore in FY26, up 36.6% from ₹4,152 crore in FY25, reflecting the company's ongoing capital expenditure program.
• Capital Work in Progress (CWIP) stands at ₹3,046 crore in FY26, up from ₹1,408 crore in FY25, indicating a massive ₹1,638 crore addition to under-construction assets. This signals significant expansion projects underway.
• Fixed assets stand at ₹6,157 crore in FY26, marginally lower than ₹6,292 crore in FY25, suggesting some assets have been capitalized from CWIP while depreciation offsets additions.
• Other liabilities surged to ₹3,973 crore in FY26 from ₹2,516 crore in FY25, a 57.9% jump that warrants monitoring.

Debt Metrics

The debt-to-equity ratio (Borrowings / (Equity + Reserves)) stands at approximately 0.80x in FY26, up from 0.63x in FY25. While this is manageable, the rising debt trajectory bears watching, especially given the ₹3,046 crore CWIP — much of which will likely be funded through additional debt before generating returns.

The interest cost has risen sharply from ₹195 crore in FY23 to ₹353 crore in FY26, an 81% increase in three years. In the March 2026 quarter alone, interest expense was ₹93 crore, contributing to margin pressure.

Cash Flow Analysis

Annual Cash Flow Summary (FY2015–FY2026)

Cash Flow Observations:

• Cash from operations (CFO) was ₹206 crore in FY26, a dramatic fall from ₹1,880 crore in FY25. This 89% decline is the most concerning data point, indicating working capital stress or earnings quality issues.
• Capex (investing outflow) surged to ₹1,559 crore in FY26, the highest in the company's history, aligning with the massive CWIP buildup.
• Free cash flow turned deeply negative at ₹-1,386 crore in FY26, compared to positive ₹763 crore in FY25. The company is in a heavy investment phase.
• Financing inflow of ₹1,376 crore in FY26 confirms the company is funding its expansion through debt, consistent with the ₹1,518 crore increase in borrowings.
• The CFO-to-Operating Profit ratio stood at just 28% in FY26, well below the 120% achieved in FY25, suggesting that reported profits are not translating into cash efficiently.

Financial Ratios: Efficiency and Returns

Key Ratios (FY2015–FY2026)

Ratio Analysis:

• ROCE peaked at 25% in FY23 but has since declined to 12% in FY26 (and 11.6% on a trailing basis), reflecting the impact of heavy capex on employed capital without commensurate profit growth.
• The cash conversion cycle widened to 55 days in FY26 from 22 days in FY25, indicating slower collections or faster inventory build-up.
• Debtor days increased to 74 in FY26 from 57 in FY25, suggesting customers are taking longer to pay.
• Inventory days also rose to 79 from 58, potentially reflecting higher raw material stocking or slower offtake.
• Days payable improved to 98 days, meaning the company is stretching its own payments to suppliers — a working capital management tactic.

Shareholding Pattern: Institutional Interest Trends

The shareholding data reveals important trends in ownership:

Shareholding Insights:

• Promoter holding has been stable at 45.63% for the last three years (FY24–FY26), indicating no pledge-related concerns or stake reduction.
• FII holding has declined from 19.09% in FY23 to 10.31% in FY26, a consistent reduction over three years. This 8.78 percentage point exit by foreign investors partly explains the stock's underperformance from its highs.
• DII holding has surged from 2.13% in FY23 to 13.24% in FY26, a 11.11 percentage point increase. Domestic mutual funds and insurance companies have been aggressively accumulating, providing a floor to the stock price.
• Retail/public holding has declined from 38.45% in FY24 to 30.83% in FY26, suggesting profit booking by smaller investors.
• The total number of shareholders stands at 1,96,724 in FY26, down from a peak of 2,38,094 in FY24, indicating some consolidation of holdings.

Peer Comparison

Deepak Fertilisers operates in the Commodity Chemicals sub-sector within Chemicals & Petrochemicals. Here's how it stacks up against peers:

Peer Analysis:

• Deepak Fertilisers is the third-largest company in its peer group by market cap at ₹17,807 crore, behind SRF (₹79,922 crore) and Tata Chemicals (₹18,699 crore).
• Its P/E of 24.15x is mid-range — cheaper than SRF (42x) and Tanfac (58.66x) but significantly more expensive than G N FC (9.08x) and GHCL (8.95x).
• The ROCE of 11.6% is moderate — better than Tata Chemicals (3.6%) and Gujarat Alkalies (1.4%) but lower than GHCL (18.0%), SRF (14.6%), and Tanfac (23.7%).
• G N FC stands out with a lower P/E (9.08x), higher dividend yield (3.61%), and improving profitability (Qtr profit +87.7%), making it a direct comparable that looks cheaper on several metrics.
• Deepak's quarterly profit declined 49.7% YoY, the worst among peers that reported profits, while G N FC showed +87.7% growth and SRF showed +12.4%.

Investment Thesis: Strengths and Opportunities

Competitive Moats

1. Sole Manufacturer Advantage: Deepak is India's only manufacturer of Prilled Ammonium Nitrate, Medical-grade Ammonium Nitrate, and NP prill 24:24:0 fertilizer. These monopoly positions provide pricing power and stable demand.

2. Backward Integration: The company's integrated production chain — from ammonia to nitric acid to finished products — provides cost advantages and supply security that few competitors can match.

3. Diversified Revenue Streams: Unlike pure-play fertilizer or chemical companies, Deepak's presence across industrial chemicals, mining explosives, crop nutrition, and IPA provides natural hedging against sector-specific downturns.

4. Market Leadership: The company holds leadership positions in Bentonite Sulphur, specialty fertilizers, and water-soluble fertilizers — high-growth segments driven by India's push toward precision agriculture.

5. Infrastructure & Mining Demand: Technical Ammonium Nitrate (TAN) demand is structurally linked to India's infrastructure buildout, highway construction, and mining activity — all multi-decade growth themes.

Growth Drivers

• Ongoing Capex: The ₹3,046 crore CWIP as of FY26 suggests substantial capacity expansion underway. When commissioned, this should drive revenue growth and potentially improve margins through operating leverage.
• Specialty Fertilizer Push: Government policies encouraging balanced nutrition and micro-nutrient usage position Deepak's specialty fertilizer portfolio for above-market growth.
• IPA Demand Growth: With India's pharmaceutical and chemical manufacturing expanding, IPA demand should grow at 8-10% annually.

Risk Factors and Concerns

1. Earnings Decline Trajectory

The most immediate concern is the declining profitability trend. FY26 net profit of ₹739 crore is down 21.8% from FY25, and the March 2026 quarter EPS of ₹11.04 is less than half the March 2025 quarter's ₹21.96. If this trend continues, the stock's P/E of 24.2x may not be justified.

2. Margin Compression

Operating margins have contracted from 19% in FY25 to 15% in FY26, with the last two quarters at just 12%. Rising raw material costs, increased competition, and pricing pressures in commodity chemicals could sustain this compression.

3. High Debt and Negative Free Cash Flow

Borrowings of ₹5,670 crore with negative FCF of ₹-1,386 crore in FY26 indicate the company is in a capital-intensive expansion phase funded primarily by debt. Interest costs of ₹353 crore annually (₹93 crore per quarter) eat into profitability. If capex projects face delays or cost overruns, the debt burden could become more concerning.

4. Working Capital Deterioration

The cash conversion cycle widened to 55 days from 22 days, and CFO collapsed from ₹1,880 crore to ₹206 crore. This suggests the company is either stocking inventory ahead of demand or facing collection challenges.

5. FII Exodus

Foreign institutional investors have reduced their stake from 19.09% in FY23 to 10.31% in FY26. While DIIs have compensated, sustained FII selling creates overhang and limits re-rating potential.

6. Possible Interest Capitalization

The machine-generated screener flags that "Company might be capitalizing the interest cost." With ₹3,046 crore in CWIP, a portion of the ₹353 crore annual interest expense may be getting capitalized to the balance sheet rather than hitting the P&L, artificially inflating reported profits. This warrants careful scrutiny.

7. Government Policy Risk

Fertilizer subsidies and pricing policies remain subject to government discretion. Any adverse policy changes could impact the fertilizer segment's profitability.

Pros and Cons Summary

✅ Pros

• Healthy dividend payout of 18.1% — provides income while you wait
• Monopoly positions in prilled ammonium nitrate and NP prill fertilizer
• Strong brand and market leadership in specialty fertilizers
• Diversified business model reducing single-sector risk
• Ongoing capacity expansion positions for future growth
• DII confidence — domestic institutions increased stake to 13.24%

❌ Cons

• Trading at 2.60x book value — premium valuation
• Low ROE of 11.3% over last 3 years — below cost of equity
• Possible interest capitalization inflating reported profits
• Declining profitability — FY26 EPS down 21% YoY
• Rising debt — borrowings up 36.6% to ₹5,670 crore
• Negative free cash flow of ₹-1,386 crore
• FII selling pressure — stake down to 10.31%

Valuation and Target Assessment

At the current price of ₹1,411 with trailing EPS of ₹58.40, the stock trades at a P/E of 24.2x. The key question is whether earnings have bottomed or will decline further.

Scenario Analysis:

The stock appears fairly to slightly expensively valued at current levels if earnings stabilize. For meaningful upside, the company needs to demonstrate:

1. Operating margin recovery to the 17-19% range
2. Successful commissioning of capex projects on time and budget
3. Improvement in cash flow generation
4. Stabilization of FII selling

Conclusion

Deepak Fertilisers & Petrochemicals Corporation Ltd is a fundamentally sound company with irreplaceable market positions, a diversified business model, and a track record of 13% revenue CAGR over the past decade. Its monopoly in prilled ammonium nitrate and specialty fertilizer leadership provide durable competitive advantages.

However, the current financial picture is one of transition. The company is investing heavily in expansion (CWIP of ₹3,046 crore), which has compressed margins, increased debt, and consumed cash flow. The 21% decline in FY26 EPS and margin contraction to 12-15% suggest the market needs to see execution on the capex program before re-rating the stock.

At ₹1,411 (P/E 24.2x), the stock is not cheap for a company with 11.3% ROE and declining earnings. Investors with a 2-3 year horizon may find value if the capex-driven growth materializes, but near-term risk-reward appears balanced to slightly unfavorable. The strong DII accumulation (13.24% stake) provides confidence that institutional investors see long-term value, but the continued FII exit (down to 10.31%) is a cautionary signal.

Investment Rating: HOLD for existing investors; WAIT for fresh entries until earnings stabilization is confirmed.

Data sourced from Screener.in as of June 1, 2026. This article is for informational purposes only and does not constitute investment advice. Please consult a SEBI-registered investment advisor before making investment decisions.

© NiftyBrief | Equity Research